{"prompt": "['Protocol RS-001', 'Confidential', 'recruitment, payment or compensation procedures, or other pertinent information) will be', \"submitted to the IRB. The IRB's written unconditional approval of the study protocol and the\", 'informed consent form will be in the possession of the Investigator before the study is initiated.', \"The IRB's unconditional approval statement will be transmitted by the Investigator to AADi\", 'prior to the shipment of study supplies to the site. This approval must refer to the study by exact', 'protocol title and number and should identify the documents reviewed and the date of review.', 'Protocol and/or informed consent modifications or changes may not be initiated without prior', 'written IRB approval except when necessary to eliminate immediate hazards to the participants', 'or when the change(s) involves only logistical or administrative aspects of the study. Such', 'modifications will be submitted to the IRB and written verification that the modification was', 'submitted and subsequently approved should be obtained.', 'The IRB must be informed of revisions to other documents originally submitted for review,', 'serious and/or unexpected adverse experiences occurring during the study in accordance with the', 'standard operating procedures and policies of the IRB, new information that may affect', 'adversely the safety of the participants of the conduct of the study, an annual update and/or', 'request for re-approval, and when the study has been completed.', '17.3', 'Informed Consent Form', 'Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH GCP, US', 'Code of Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], CFR 50.27,', 'and CFR Part 56, Subpart A), the Health Insurance Portability and Accountability Act (HIPAA,', 'if applicable), and local regulations.', 'The Investigator will prepare the informed consent form, assent and HIPAA authorization and', 'provide the documents to the Sponsor or designee for approval prior to submission to the IRB.', 'The consent form generated by the Investigator must be acceptable to the Sponsor and be', 'approved by the IRB. The written consent document will embody the elements of informed', 'consent as described in the International Conference on Harmonisation and will also comply', 'with local regulations. The Investigator will send an IRB-approved copy of the Informed', 'Consent Form to the Sponsor (or designee) for the study file.', 'A properly executed, written, informed consent will be obtained from each participant prior to', 'entering the participant into the trial. Information should be given in both oral and written form', 'and participants (or their legal representatives) must be given ample opportunity to inquire about', 'details of the study. If appropriate and required by the local IRB, assent from the participant will', 'also be obtained. If a participant is unable to sign the informed consent form (ICF) and the', 'HIPAA authorization, a legal representative may sign for the participant. A copy of the signed', 'consent form (and assent) will be given to the participant or legal representative of the', \"participant and the original will be maintained with the participant's records.\", 'During the course of the study, if modifications are made to the consent form that impact the', 'participant, the participant will be re-consented as described above.', '17.4 Publications', 'The preparation and submittal for publication of manuscripts containing the study results shall be', 'in accordance with a process determined by mutual written agreement among the study Sponsor', 'and participating institutions. The publication or presentation of any study results shall comply', 'Version 2', 'Version Date: October 31, 2018', 'Page 61 of 72']['Protocol RS-001', 'Confidential', 'with all applicable privacy laws, including, but not limited to, the Health Insurance Portability', 'and Accountability Act of 1996.', '17.5 Investigator Responsibilities', 'By signing the Agreement of Investigator form, the Investigator agrees to:', '1. Conduct the study in accordance with the protocol and only make changes after notifying the', 'Sponsor (or designee), except when to protect the safety, rights or welfare of subjects.', '2. Personally conduct or supervise the study (or investigation).', '3. Ensure that the requirements relating to obtaining informed consent and IRB review and', 'approval meet federal guidelines, as stated in \u00a7 21 CFR, parts 50 and 56.', '4. Report to the Sponsor or designee any AEs that occur in the course of the study, in', 'accordance with \u00a721 CFR 312.64.', '5. Ensure that all associates, colleagues and employees assisting in the conduct of the study are', 'informed about their obligations in meeting the above commitments.', '6. Maintain adequate and accurate records in accordance with \u00a721 CFR 312.62 and to make', 'those records available for inspection with the Sponsor (or designee).', '7. Ensure that an IRB that complies with the requirements of \u00a721 CFR part 56 will be', 'responsible for initial and continuing review and approval of the clinical study.', '8. Promptly report to the IRB and the Sponsor (or designee) all changes in the research activity', 'and all unanticipated problems involving risks to subjects or others (to include amendments', 'and IND safety reports).', '9. Seek IRB approval before any changes are made in the research study, except when', 'necessary to eliminate hazards to the participants/subjects.', '10. Comply with all other requirements regarding the obligations of clinical investigators and all', 'other pertinent requirements listed in \u00a7 21 CFR part 312.', '18 REFERENCES', '1.', 'Sabaz, M., et al., Validation of the quality of life in childhood epilepsy questionnaire in', 'American epilepsy patients. Epilepsy Behav, 2003. 4(6): p. 680-91.', '2.', 'Aman, M.G., et al., The Nisonger CBRF: a child behavior rating form for children with', 'developmental disabilities. Res Dev Disabil, 1996. 17(1): p. 41-57.', '3.', 'Tasse, M.J., et al., The Nisonger Child Behavior Rating Form: age and gender effects', 'and norms. Res Dev Disabil, 1996. 17(1): p. 59-75.', '4.', 'Shields, W.D., et al., Treatment of infantile spasms: medical or surgical? Epilepsia,', '1992. 33 Suppl 4: p. S26-31.', '5.', 'Jonas, R., et al., Surgery for symptomatic infant-onset epileptic encephalopathy with and', 'without infantile spasms. Neurology, 2005. 64(4): p. 746-50.', '6.', 'Olafsson, E., et al., Incidence of unprovoked seizures and epilepsy in Iceland and', 'assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol,', '2005. 4(10): p. 627-34.', 'Version 2', 'Version Date: October 31, 2018', 'Page 62 of 72']\n\n###\n\n", "completion": "END"}